TFL Gallery / t-cibic-week8

EFF03 · Table

CIBIC+ — Summary at Week 8 — LOCF

The CIBIC+ global impression read at Week 8, same model.

Slug
t-cibic-week8
Regulatory ID
EFF03
Type
Table
E3 position
§14.2
Status
evidenced
Current iteration
v002
Datasets
adqscibc f6461f4, adsl 70c7278
Evidence
22/22 passing
Requirements
DSP-ALL-001 DSP-ALL-002 DSP-CIBIC-001 DSP-CIBIC-002 DSP-CIBIC-003 DSP-CIBIC-004 DSP-CIBIC-005 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
Used in
Study model
Efficacy Analysis Set EFFFL · grouped by TRT01A
Specification
2 iterations
Environment
R 4.3.3 Darwin 23.6.0
Bound by
No text block binds it
Values
No value is sourced from it
Inputs
Function
Outputs

Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.

t-cibic-week8 · post_text variant · study CDISCPILOT01 · data cut-off 2014-07-01

CIBIC+ — Summary at Week 8 — LOCF
Study CDISCPILOT01 — Efficacy Analysis Set
Placebo (N=79) Xanomeline Low Dose (N=81) Xanomeline High Dose (N=74)
Week 8
   n 77 81 73
   Mean (SD) 3.9 (0.73) 4.0 (0.72) 4.1 (0.75)
   Median (Range) 4.0 (2; 6) 4.0 (2; 6) 4.0 (2; 6)
Analysis of covariance
   p-value (dose response) 0.167
   p-value (Xanomeline − Placebo) 0.754 0.128
      Difference of LS means (SE) 0.0 (0.12) 0.2 (0.12)
      95% CI (-0.2; 0.3) (-0.1; 0.4)
   p-value (Xanomeline High − Xanomeline Low) 0.218
      Difference of LS means (SE) 0.1 (0.12)
      95% CI (-0.1; 0.4)
A supporting analysis at an earlier time point. The primary endpoint is CIBIC+ at Week 24.
The Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+) is scored 1 (marked improvement) to 7 (marked worsening); 4 is no change. A higher score is a worse outcome.
Values are last observation carried forward within the analysis window (ADQSCIBC ANL01FL = 'Y').
Column headings are the size of the efficacy analysis set; n is the number of subjects with a value at this visit.
Model: analysis of covariance with treatment and site group as factors. The dose-response p-value tests a non-zero coefficient for treatment entered as randomised dose (0, 54 or 81 mg), and is a single model-level result, printed once.
Pairwise comparisons treat treatment as a categorical variable and are not adjusted for multiplicity. The study's analysis plan directs that they not be interpreted unless the dose-response test is significant.
Source: adqscibc, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01.
open.csr display t-cibic-week8 (post_text variant); generated from the committed ARD.

Rendered from outputs/t-cibic-week8/v002/table.html.

Every iteration is kept: outputs/t-cibic-week8/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.